Guideline “Motor neuron diseases” of the German Society of Neurology (Deutsche Gesellschaft für Neurologie)
-
Published:2023-06-15
Issue:1
Volume:5
Page:
-
ISSN:2524-3489
-
Container-title:Neurological Research and Practice
-
language:en
-
Short-container-title:Neurol. Res. Pract.
Author:
Petri SusanneORCID, Grehl Torsten, Grosskreutz Julian, Hecht Martin, Hermann Andreas, Jesse Sarah, Lingor Paul, Löscher Wolfgang, Maier André, Schoser Benedikt, Weber Marcus, Ludolph Albert C.
Abstract
Abstract
Introduction
In 2021, the Deutsche Gesellschaft für Neurology published a new guideline on diagnosis and therapy of motor neuron disorders. Motor neuron disorders affect upper motor neurons in the primary motor cortex and/or lower motor neurons in the brain stem and spinal cord. The most frequent motor neuron disease amyotrophic lateral sclerosis (ALS) is a rapidly progressive disease with an average life expectancy of 2–4 years with a yearly incidence of 3.1/100,000 in Central Europe (Rosenbohm et al. in J Neurol 264(4):749–757, 2017. https://doi.org/10.1007/s00415-017-8413-3). It is considered a rare disease mainly due to its low prevalence as a consequence of short disease duration.
Recommendations
These guidelines comprise recommendations regarding differential diagnosis, neuroprotective therapies and multidisciplinary palliative care including management of respiration and nutrition as well as provision of assistive devices and end-of-life situations.
Conclusion
Diagnostic and therapeutic guidelines are necessary due the comparatively high number of cases and the aggressive disease course. Given the low prevalence and the severe impairment of patients, it is often impossible to generate evidence-based data so that ALS guidelines are partially dependent on expert opinion.
Publisher
Springer Science and Business Media LLC
Subject
Neurology (clinical),Neurology
Reference64 articles.
1. Abe, K., Itoyama, Y., Sobue, G., Tsuji, S., Aoki, M., Doyu, M., Edaravone ALS Study Group. (2014). Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotrophic Lateral Sclerosis Frontotemporal Degeneration, 15(7–8), 610–617. https://doi.org/10.3109/21678421.2014.959024 2. Andersen, P. M., Abrahams, S., Borasio, G. D., de Carvalho, M., Chio, A., Van Damme, P., & Weber, M. (2012). EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)—Revised report of an EFNS task force. European Journal of Neurology, 19(3), 360–375. https://doi.org/10.1111/j.1468-1331.2011.03501.x 3. Andersen, P. M., Borasio, G. D., Dengler, R., Hardiman, O., Kollewe, K., Leigh, P. N., Management of Amyotrophic Lateral, S. (2005). EFNS task force on management of amyotrophic lateral sclerosis: Guidelines for diagnosing and clinical care of patients and relatives. European Journal of Neurology, 12(12), 921–938. https://doi.org/10.1111/j.1468-1331.2005.01351.x 4. Andrews, J. A., Jackson, C. E., Heiman-Patterson, T. D., Bettica, P., Brooks, B. R., & Pioro, E. P. (2020). Real-world evidence of riluzole effectiveness in treating amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener, 21(7–8), 509–518. https://doi.org/10.1080/21678421.2020.1771734 5. Assouline, A., Levy, A., Abdelnour-Mallet, M., Gonzalez-Bermejo, J., Lenglet, T., Le Forestier, N., & Pradat, P. F. (2014). Radiation therapy for hypersalivation: A prospective study in 50 amyotrophic lateral sclerosis patients. International Journal of Radiation Oncology Biology Physics, 88(3), 589–595. https://doi.org/10.1016/j.ijrobp.2013.11.230
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|